Zhankuic acid A, a JAK2/3 tyrosine kinase inhibitor, and a potential therapeutic agent for hepatitis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 29, 2015
app pub date -
Apr 24, 2015
filing date -
Apr 25, 2014
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Zhankuic acid A (ZAA) could suppress phosphorylation of JAK2 and JAK3 and signaling of downstream molecules. Moreover, ZAA could inhibit the IFN-γ/STAT1/IRF-1 pathway in vivo and in vitro. Furthermore, data show that pre-treatment with ZAA could significantly ameliorate Con A-induced hepatitis in mice. The above results strongly suggest that ZAA treatment could block JAK2 and JAK3 activation, and may be a valuable therapeutic approach for the treatment of immune cell induced inflammation.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully